Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$1.41
+1.1%
$1.94
$0.90
$4.98
$353.70M2.453.88 million shs2.33 million shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$4.63
+1.0%
$4.42
$2.03
$5.81
$89.02M1.01108,473 shs83,861 shs
RxSight, Inc. stock logo
RXST
RxSight
$8.40
+14.2%
$10.74
$6.32
$58.23
$343.52M1.161.03 million shs1.17 million shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.90
+1.0%
$3.83
$0.52
$5.92
$257.89M1.781.21 million shs1.17 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
+1.47%+2.97%-23.48%-39.78%+45.79%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+1.33%-6.15%+9.57%+25.14%-8.40%
RxSight, Inc. stock logo
RXST
RxSight
+10.53%-3.92%-8.13%-44.49%-85.91%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-1.53%-15.16%+8.12%-10.23%+418.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
2.1836 of 5 stars
3.41.00.00.02.32.50.6
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.562 of 5 stars
0.02.00.00.03.00.80.6
RxSight, Inc. stock logo
RXST
RxSight
2.2487 of 5 stars
3.04.00.00.01.61.70.6
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.9843 of 5 stars
3.51.00.00.02.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
2.75
Moderate Buy$3.00113.52% Upside
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.00
N/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
1.91
Reduce$10.0019.12% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
3.00
Buy$5.0028.21% Upside

Current Analyst Ratings Breakdown

Latest NVNO, BFLY, RXST, and STIM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$9.00 ➝ $8.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $11.00
8/6/2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/4/2025
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingPositive ➝ Positive$2.00
8/1/2025
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
7/15/2025
RxSight, Inc. stock logo
RXST
RxSight
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.00
7/10/2025
RxSight, Inc. stock logo
RXST
RxSight
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$24.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $9.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$82.06M4.31N/AN/A$0.92 per share1.53
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$1.72 per shareN/A
RxSight, Inc. stock logo
RXST
RxSight
$139.93M2.45N/AN/A$6.79 per share1.24
Neuronetics, Inc. stock logo
STIM
Neuronetics
$111.11M2.32N/AN/A$0.48 per share8.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$72.49M-$0.28N/AN/AN/A-71.79%-30.53%-21.80%N/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%10/29/2025 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$27.45M-$0.80N/AN/AN/A-21.93%-11.56%-10.31%N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$43.71M-$1.13N/AN/AN/A-43.47%-156.36%-35.69%N/A

Latest NVNO, BFLY, RXST, and STIM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Guidance Update
RxSight, Inc. stock logo
RXST
RxSight
-$0.04-$0.08-$0.04-$0.29$39.78 million$33.64 million
8/5/2025Q2 2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.08-$0.15-$0.07-$0.15$36.80 million$38.11 million
8/1/2025Q2 2025
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$0.07-$0.06+$0.01-$0.06$23.91 million$23.38 million
7/31/2025Q2 2025
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$0.28-$0.33-$0.05-$0.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/A
5.68
4.14
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
11.81
11.81
RxSight, Inc. stock logo
RXST
RxSight
N/A
13.93
11.65
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.76
2.02
1.84

Institutional Ownership

CompanyInstitutional Ownership
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
37.85%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%
RxSight, Inc. stock logo
RXST
RxSight
78.78%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
25.18%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
16.00%
RxSight, Inc. stock logo
RXST
RxSight
9.57%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
460251.74 million188.35 millionOptionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
3019.25 million16.17 millionOptionable
RxSight, Inc. stock logo
RXST
RxSight
22040.92 million37.00 millionOptionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
18066.13 million59.65 millionOptionable

Recent News About These Companies

Neuronetics taps local industry veteran as new CFO
Neuronetics Appoints New Chief Financial Officer
Neuronetics Appoints New Chief Financial Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Butterfly Network stock logo

Butterfly Network NYSE:BFLY

$1.40 +0.02 (+1.08%)
As of 02:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

enVVeno Medical stock logo

enVVeno Medical NASDAQ:NVNO

$4.62 +0.05 (+0.98%)
As of 02:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

RxSight stock logo

RxSight NASDAQ:RXST

$8.40 +1.05 (+14.22%)
As of 02:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Neuronetics stock logo

Neuronetics NASDAQ:STIM

$3.90 +0.04 (+1.04%)
As of 02:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.